Kitov Pharma to Present New Data on NT-219 Targeting Cancer Drug Resistance at the AACR Pancreatic Cancer: Advances in Science and Clinical Care Conference

Pharma to Present New Data on NT-219 Targeting Cancer Drug Resistance at the AACR Pancreatic Cancer: Advances in Science and Clinical

AVIV, Israel, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV),

a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced

that Kitov's subsidiary, TyrNovo, will present new data at the American Association for Cancer Research (AACR) Pancreatic

Cancer: Advances in Science and Clinical Care conference being held September 6 - 9, 2019 in Boston.

poster presentation will showcase new data on NT-219, Kitov's developmental first-in-class, small molecule, dual inhibitor

of the two common cancer resistance pathways STAT3 and IRS1/2. Kitov is advancing NT-219 primarily for the treatment of recurrent

and metastatic squamous cell carcinoma of head & neck cancer (SCCHN) and exploring its potential in additional oncology indications

including pancreatic cancer.

the AACR Pancreatic Cancer: Advances in Science and Clinical Care Conference

conference will be the sixth AACR Special Conference on pancreatic cancer. According to the U.S. National Cancer Institute, pancreatic

cancer will account for approximately 44,330 deaths in 2018 and is poised to become the third leading cause of cancer deaths by

2030. As the field continues to grow, it is imperative that researchers can interact, share data, and discuss ideas to help reach

the overall goal of improved treatment for pancreatic cancer. The conference will showcase sessions on tumor heterogeneity, immunology,

prevention and early detection, and novel treatment combinations, among others.

Pharma (Kitov Pharma Ltd.; NASDAQ/TASE: KTOV) is a clinical-stage company advancing first-in-class therapies to overcome tumor

immune evasion and drug resistance, to create successful long-lasting treatments for people with cancer. Kitov's oncology

pipeline includes NT-219, a small molecule targeting the novel cancer drug resistance pathways IRS1/2 and STAT3. Kitov is currently

advancing NT-219 in combination with cetuximab as a third-line or second-line treatment option for the treatment of recurrent

and metastatic squamous cell carcinoma of head & neck cancer (SCCHN). Kitov is also under contract to acquire 100% of FameWave

Ltd. which owns CM-24, a monoclonal antibody blocking CEACAM1, a novel immune checkpoint that supports tumor immune evasion and

survival through multiple pathways. Kitov will advance CM-24 as a combination therapy with anti-PD1 checkpoint inhibitors in a

clinical collaboration agreement with Bristol Myers Squibb (NYSE:BMY) in a planned Phase 1/2 clinical trials to evaluate the combination

of CM-24 with the PD-1 inhibitor nivolumab (Opdivo ) for the treatment of non-small cell lung cancer (NSCLC) All major closing

conditions have been met other than finalizing the tax ruling for the sellers and the issuance and exchange of shares in the companies

and the acquisition is expected to close during the third quarter of 2019. Consensi, a fixed-dose combination of celecoxib

and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension was approved by the FDA for marketing

in the U.S in May 2018 and is expected to be launched in the U.S. at the end of 2019 by its partner Coeptis Pharmaceuticals. Kitov

has also partnered to commercialize Consensi in China and South Korea.

company is headquartered in Tel Aviv, Israel. For more information, please visit http://www.kitovpharma.com.

Statements and Kitov's Safe Harbor Statement

statements in this press release that are forward-looking and not statements of historical fact are forward-looking

statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such

forward-looking statements include, but are not limited to, statements that are not statements of historical fact, and may be

identified by words such as "believe", "expect", "intend", "plan",

"may", "should", "could", "might", "seek", "target",

"will", "project", "forecast", "continue" or "anticipate" or

their negatives or variations of these words or other comparable words or by the fact that these statements do not relate

strictly to historical matters. You should not place undue reliance on these forward-looking statements, which are not

guarantees of future performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions

with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are

beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements

to be significantly different from any future results, performance or achievements expressed or implied by the

forward-looking statements. Important factors that could cause or contribute to such differences include, among others, risks

relating to: the manner in which the parties to the transaction for the acquisition of FameWave by Kitov plan to effect the

closing of the transaction; the expected benefits, synergies and costs of the transaction; management plans relating to the

transaction; the expected timing of the completion of the transaction; the parties' ability to complete the

transaction considering the various closing conditions; the plans, strategies and objectives of management for future

operations; product development for NT219 and CM-24; the potential future financial impact of the transaction; and any

assumptions underlying any of the foregoing; the process by which early stage products such as CM-24 could potentially

lead to an approved product is long and subject to highly significant risks, particularly with respect to a joint development

collaboration; the fact that drug development and commercialization involves a lengthy and expensive process with uncertain

outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length, progress

and results of any clinical trials; the lack of sufficient funding to finance the clinical trials; the impact of any changes

in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory

approvals necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug

Administration or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the

health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to

our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products;

patents attained by competitors; dependence on the effectiveness of our patents and other protections for innovative

products; our ability to obtain, maintain and defend issued patents with protective claims; the commencement of any patent

interference or infringement action; our ability to prevail, obtain a favorable decision or recover damages in any such

action; and the exposure to litigation, including patent litigation, and/or regulatory actions; any continued uncertainty

surrounding an investigation by the Israel Securities Authority into our historical public disclosures which was

settled under an administrative enforcement proceeding, and the potential impact of such investigation and settlement on the

trading of our securities or on our clinical, commercial and other business relationships, or on receiving the regulatory

approvals necessary in order to commercialize our products, and other factors that are discussed in our in our Annual Report

on Form 20-F for the year ended December 31, 2018 and in our other filings with the SEC, including our cautionary discussion

of risks and uncertainties under Risk Factors' in our Registration Statements and Annual Reports. These are

factors that we believe could cause our actual results to differ materially from expected results. Other factors besides

those we have listed could also adversely affect us. Any forward-looking statement in this press release speaks only as of

the date which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking

statement, or other information contained herein, whether as a result of new information, future events or otherwise, except

as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the

SEC, which are available on the SEC's website, http://www.sec.gov For further information, contact:

Deputy CEO & Chief Financial Officer

+972-3-933-3121 ext. #105

Darren Opland, Ph.D.